Italy

Takis Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Applied DNA, Takis Announce Positive Preclinical Results from LineaDNA Vaccine Candidates for COVID-19

Lead Product(s): LineaDNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Applied DNA Sciences Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 17, 2020

Details:

All animals demonstrated seroconversion to producing IgG against SARS-CoV-2 Spike Protein already by day 14, and significantly enhanced responses by day 38.

Takis Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Rottapharm Biotech and Takis Enter an Agreement for the Co-Development of the Vaccine Against COVID-19

Lead Product(s): COVID-eVax

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Rottapharm Biotech

Deal Size: Undisclosed Upfront Cash: $3.3 million

Deal Type: Collaboration June 04, 2020

Details:

Under the terms of this collaboration, Rottapharm Biotech will provide Takis with operational support, and with the financial resources needed to complete Phase I/II clinical trials.

Takis Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Takis Vaccines Neutralize SARS-CoV-2

Lead Product(s): DNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

Researchers at National Institute of Infectious Diseases found that Takis vaccines after a single vaccination developed antibodies in mice that can block the infection of SARS-CoV-2 on human cells.

ReiThera

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

After The USA And Australia, The First Pre-Clinical Animal Tests Are Also Carried Out In Italy

Lead Product(s): Covid-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 17, 2020

Details:

The vaccine developed by ReiThera has been obtained from a fragment of the genetic material of the virus and is based on the technology called electroporation.

Takis Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Applied DNA Sciences Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed

Lead Product(s): Linear DNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Applied DNA Sciences Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 02, 2020

Details:

Applied DNA is expected to enter large-scale production of candidates in march; preclinical testing in animals by takis biotech anticipated to begin in calendar Q2 2020.

Takis Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Applied DNA and Takis Biotech partner on coronavirus vaccine

Lead Product(s): Linear DNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Applied DNA Sciences Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 10, 2020

Details:

LineaRx, a subsidiary of Applied DNA, will work with Takis Biotech on preclinical development of a linear DNA vaccine based on polymerase chain reaction (PCR).

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Takis Biotech

Applied DNA, Takis Announce Positive Preclinical Results from LineaDNA Vaccine Candidates for COVID-19

Takis Biotech

Rottapharm Biotech and Takis Enter an Agreement for the Co-Development of the Vaccine Against COVID-19

Takis Biotech

Takis Vaccines Neutralize SARS-CoV-2

ReiThera

After The USA And Australia, The First Pre-Clinical Animal Tests Are Also Carried Out In Italy

Takis Biotech

Applied DNA Sciences Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed

Takis Biotech

Applied DNA and Takis Biotech partner on coronavirus vaccine